Scientists have developed the first immoral red blood cell line to crack the blood transfusion trap.

Biotechnology Channel News: Researchers have developed the first immoral red blood cell line that can make red blood cells more efficiently.
now, research teams from the University of Bristol and NHS Blood and Transplant (NHSBT) have been able to produce red blood cells more efficiently than never before.
the team's findings, published in the journal Nature Communications, could provide a safe source of blood transfusions for rare blood types and benefit areas of the world where blood supplies are inadequate or blood is unsafe.
past, donated stem cells were grown directly into mature red blood cells.
, however, this method produces only a small amount of mature red blood cells and requires repeated donations.
today, a leading world-leading team at the University of Bristol has developed a stable, repeatable technique that can produce permanently biotic red blood cells from adult stem cells.
these immature red blood cells can proliferate indefinitely and can be mass-produced before they differentiate into mature red blood cells.
Frayne, of the University of Bristol's School of Biochemistry, said: "In the past, the production of red blood cells relied on stem cells from different sources, but at present the production of stem cells is extremely limited.
To find another way to create the first permanently biotic human adult erythrocyte line (Bristol Erythroid Line Adult or BEL-A), it is feasible to continuously produce red blood cells through in vitro culture to meet clinical needs.
"medical institutions around the world need a replacement for red blood cells."
in-body culture is superior in some respects to donated blood, for example by reducing the risk of spreading infectious diseases.
red blood cell product developed by NHSBT Research is the result of a collaboration between NHSBT and the University of Bristol.
, director of research at the University of London, said: "Scientists have been working for years on how to make red blood cells instead of donated blood to treat patients.
red blood cell products may be used first to treat patients with rare blood types because they have difficulty getting the right blood through regular donations.
" "The patients most likely to benefit are those with complex conditions and limited survival, such as sickle cell disease and thalassemia, who require not only highly matched blood supply, but also multiple blood transfusions."
our goal is not to replace blood donation, but to provide specific treatments for specific groups of patients.
" red blood cell culture is currently being carried out at the University of Bristol and NHSBT's Filtonsite base.
NHSBT collects 1.5 million units of blood a year to meet the needs of patients in England and continues to need blood donations for first aid.
condition will continue for many years before large-scale use of artificial red blood cells.
2015, NHSBT unveiled a human trial of artificial blood.
trial will begin at the end of 2017 and will not use Bel-A cells, but will use artificial red blood cells grown from stem cells from conventional blood donations.
.